Onconic Therapeutics to Earn from Jacuvo and Grow Anticancer and Obesity New Drugs [Why Bio]
Predicted impact: Low
Royalty and pipeline commentary; no new quantified deal.
Onconic Therapeutics온코닉테라퓨틱스
476060 · KOSDAQ · ₩476060 · 온코닉테라퓨틱스
₩12,770▲ ₩420 (3.40%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −35.51%
- Market cap
- ₩580B
- Enterprise value
- ₩522B
- P/E
- 29.4×
- P/B
- 6.8×
- Dividend yield
- 0.0%
- ROE
- 23.0%
- Net margin
- 24.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−55.8% from the high
₩8,790Today: ₩12,700 – ₩13,150₩28,900
Returns
- 1W−6.0%
- 1M−15.6%
- 3M+23.9%
- 6M−42.0%
- YTD−34.7%
- 1Y−35.5%
- Volume today
- 124,005
- 0.6× the 20-day average
- Traded today
- ₩1.6B
- Listed shares
- 45,407,840
- EPS (12 months)
- ₩434
- Earnings yield 3.4%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
- Oct 30Earnings Expected · Preliminary results
- Nov 11Earnings Expected · 3Q results
- Nov 26AGM Extraordinary shareholders' meeting
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 36 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headline points to expected earnings and pipeline growth, with no details. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-13.3% over the last month; the price is below its 20-day average.
- News impactLow8 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 27: buy ₩189M at the close (7.0% of 20-day average trading value)
On its 28 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 8.5% of trading value and pointed the same way 19 of 28 times.
- 2× KODEX KOSDAQ150 Leverage ₩155M
- 2× TIGER KOSDAQ150 Leverage ₩18M
- -1× KODEX KOSDAQ150 Futures Inverse ₩11M
- 2× RISE KOSDAQ150 Futures Leverage ₩3.2M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.2%
- KODEX KOSDAQ150 Leverage2×0.2%
- TIGER KOSDAQ1500.2%
- RISE KOSDAQ1500.2%
- TIGER KOSDAQ150 Leverage2×0.2%
- ACE KOSDAQ 1500.2%
- KIWOOM KOSDAQ1500.2%
- SOL KOSDAQ1500.2%
Estimated from the funds' index or underlying stock.
Onconic Therapeutics stock overview
Onconic Therapeutics (온코닉테라퓨틱스, KRX: 476060) is listed on KOSDAQ, in the Biotech & Pharma sector. OncoNic Therapeutics develops small-molecule innovative drugs for acid-related digestive diseases and cancer. Its shares closed at ₩12,770 on Oct 27, 2026, up 3.40% on the day, giving it a market value of ₩580B.
Key facts
- Market cap
- ₩580B
- Sector
- Biotech & Pharma
- Latest price change
- +3.40%
- As of
- Oct 27, 2026
- Main business
- OncoNic Therapeutics develops small-molecule innovative drugs for acid-related digestive diseases and cancer.
Quick answers about Onconic Therapeutics
- What does Onconic Therapeutics do?
- OncoNic Therapeutics develops small-molecule innovative drugs for acid-related digestive diseases and cancer. Its lead drug, Zastaprazan, a potassium-competitive acid blocker (P-CAB) for erosive reflux esophagitis and gastric ulcer, received Korean approval and launched in October 2024. The company is also developing Nesuparib, a PARP/tankyrase dual-inhibitor anticancer drug, and early-stage synthetic lethality cancer candidates, with clinical trials conducted in Korea.
- What is the market cap of Onconic Therapeutics?
- The market capitalisation of Onconic Therapeutics was ₩580B at the close on Oct 27, 2026.
- Who are the largest shareholders of Onconic Therapeutics?
- According to the latest official filings, the largest reported holders are Jeil Pharmaceutical (51.28%, as of Mar 4, 2026); Stonebridge Ventures (2.99%, as of Dec 23, 2024); Korea Development Bank (2.10%, as of Feb 6, 2025).
- When is the next earnings report from Onconic Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when Onconic Therapeutics filed the same report in past years, its next preliminary results is expected around Oct 30, 2026.
Company profile
OncoNic Therapeutics develops small-molecule innovative drugs for acid-related digestive diseases and cancer. Its lead drug, Zastaprazan, a potassium-competitive acid blocker (P-CAB) for erosive reflux esophagitis and gastric ulcer, received Korean approval and launched in October 2024. The company is also developing Nesuparib, a PARP/tankyrase dual-inhibitor anticancer drug, and early-stage synthetic lethality cancer candidates, with clinical trials conducted in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 온코닉테라퓨틱스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김존
- Founded
- May 2020
- Listed
- Dec 2024
- Listed shares
- 45,407,840
- Fiscal year ends
- Month 12
- Website
- onconic.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Onconic Therapeutics: "Zaqbo oral disintegrating tablet confirmed to show drug exposure equivalent to existing tablet"
Predicted impact: Low
Routine shareholders' meeting notice and proxy documents; procedural only.
Oncocross Therapeutics to expand anticancer and obesity drug development based on Jacuzbo royalties
Predicted impact: Low
Routine shareholder meeting notices already reported.
Recent filings
See all- Determination of Shareholder Register Closure Period or Record DateOct 16, 2026
- Shareholders' meeting calledOct 16, 2026
- Reference Document for Proxy Solicitation of Voting RightsOct 16, 2026
- Notice of shareholders' meetingOct 16, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsSep 3, 2026
Titles in Korean until English translations are added.
Also known as: Onconic Therapeutics / 온코닉테라퓨틱스 / 476060 / KRX:476060
Source: KRX statistical information